Literature DB >> 9700634

Viral proteins VP2, VP6, and NSP2 are strongly precipitated by serum and fecal antibodies from children with rotavirus symptomatic infection.

J Colomina1, M T Gil, P Codoñer, J Buesa.   

Abstract

Rotavirus-specific IgA has been correlated with immune protection against rotavirus reinfection and symptomatic disease. Systemic and mucosal antibody responses were determined by an enzyme-linked immunosorbent assay in 11 infants with severe rotavirus gastroenteritis. Geometric mean titers of antirotavirus serum IgG and IgA antibodies were significantly higher during the convalescence of the disease (P < 0.001 vs. acute-phase titers). Rotavirus-specific fecal sIgA antibodies increased 4 times during the convalescence in 9 (81.8%) children (P < 0.001). The serum IgG and IgA antibody and fecal sIgA antibody responses to individual rotavirus polypeptides were characterized by radioimmunoprecipitation assay (RIPA) using Staphylococcus aureus protein A and the lectin jacalin to precipitate IgG- and IgA-immune complexes, respectively. The main IgG response was directed toward the structural viral proteins VP2, VP4, and VP6 and toward the nonstructural protein NSP2. Serum IgA reactivity was detected by RIPA in all serum samples, with major responses to VP2, VP6, and NSP2. Interestingly, fecal sIgA in convalescent samples reacted strongly toward NSP2 and VP6. These data reinforce the antigenic importance of rotaviral proteins other than VP4 and VP7, such as VP2, VP6, and NSP2, as main targets in the immune response to rotavirus.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9700634     DOI: 10.1002/(sici)1096-9071(199809)56:1<58::aid-jmv10>3.0.co;2-s

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  8 in total

1.  Bifidobacterium longum subsp infantis CECT7210-supplemented formula reduces diarrhea in healthy infants: a randomized controlled trial.

Authors:  Joaquin Escribano; Natalia Ferré; Mariona Gispert-Llaurado; Veronica Luque; Carmen Rubio-Torrents; Marta Zaragoza-Jordana; Isabel Polanco; Francisco M Codoñer; Empar Chenoll; Mireia Morera; Jose Antonio Moreno-Muñoz; Montserrat Rivero; Ricardo Closa-Monasterolo
Journal:  Pediatr Res       Date:  2018-05-02       Impact factor: 3.756

2.  Resistance to rotavirus infection in adult volunteers challenged with a virulent G1P1A[8] virus correlated with serum immunoglobulin G antibodies to homotypic viral proteins 7 and 4.

Authors:  Lijuan Yuan; Shinjiro Honma; Inyoung Kim; Albert Z Kapikian; Yasutaka Hoshino
Journal:  J Infect Dis       Date:  2009-11-01       Impact factor: 5.226

3.  Antibody responses to human rotavirus (HRV) in gnotobiotic pigs following a new prime/boost vaccine strategy using oral attenuated HRV priming and intranasal VP2/6 rotavirus-like particle (VLP) boosting with ISCOM.

Authors:  A M González; T V Nguyen; M S P Azevedo; K Jeong; F Agarib; C Iosef; K Chang; K Lovgren-Bengtsson; B Morein; L J Saif
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

4.  Non-structural protein NSP2 induces heterotypic antibody responses during primary rotavirus infection and reinfection in children.

Authors:  Carl D Kirkwood; Karen Boniface; Simone Richardson; Zenobia F Taraporewala; John T Patton; Ruth F Bishop
Journal:  J Med Virol       Date:  2008-06       Impact factor: 2.327

5.  Serological responses to rotavirus NSP2 following administration of RV3-BB human neonatal rotavirus vaccine.

Authors:  Daniel Cowley; Daniel Pavlic; Nada Bogdanovic-Sakran; Karen Boniface; Carl D Kirkwood; Julie E Bines
Journal:  Hum Vaccin Immunother       Date:  2018-05-31       Impact factor: 3.452

6.  Comparative Analysis of G1P[8] Rotaviruses Identified Prior to Vaccine Implementation in Pakistan With Rotarix™ and RotaTeq™ Vaccine Strains.

Authors:  Asma Sadiq; Nazish Bostan
Journal:  Front Immunol       Date:  2020-10-02       Impact factor: 7.561

Review 7.  Advances in the Development of Antiviral Compounds for Rotavirus Infections.

Authors:  María Julieta Tohmé; Laura Ruth Delgui
Journal:  mBio       Date:  2021-05-11       Impact factor: 7.867

8.  Molecular characterisation of rotavirus strains detected during a clinical trial of the human neonatal rotavirus vaccine (RV3-BB) in Indonesia.

Authors:  Daniel Cowley; Hera Nirwati; Celeste M Donato; Nada Bogdanovic-Sakran; Karen Boniface; Carl D Kirkwood; Julie E Bines
Journal:  Vaccine       Date:  2018-08-23       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.